This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (10)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Frank M. Sacks, MD

JAMA. 2004;291:1132-1134.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of THE JOURNAL, Nissen and colleagues¹ report the findings of the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) study, a clinical trial comparing the effects of 2 statins, pravastatin (40-mg dose) and atorvastatin (80-mg dose). The REVERSAL study is a first in 2 respects. First, it showed that a statin regimen using the most efficacious drug (atorvastatin) and dose available for lowering low-density lipoprotein cholesterol (LDL-C) when the trial began improved coronary atherosclerosis more than pravastatin, which represented a statin regimen that had been fully established to safely reduce cardiovascular disease and mortality.^2-6 Second, the advantage of atorvastatin was demonstrated using an intravascular ultrasound examination of the coronary arteries, a technique that quantifies plaque by visualizing the coronary arterial intima. While this study is an important achievement, it is equally important to determine what it adds to current knowledge of lipid therapy . . . [Full Text of this Article]

Author Affiliation: Harvard School of Public Health and Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial
Steven E. Nissen, E. Murat Tuzcu, Paul Schoenhagen, B. Greg Brown, Peter Ganz, Robert A. Vogel, Tim Crowe, Gail Howard, Christopher J. Cooper, Bruce Brodie, Cindy L. Grines, and Anthony N. DeMaria
JAMA. 2004;291(9):1071-1080.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

New Developments and Novel Therapeutic Perspectives for Vitamin C
Li and Schellhorn
J. Nutr. 2007;137:2171-2184.
ABSTRACT | FULL TEXT  

An evaluation of class effect.
Zhou et al.
CMAJ 2006;174:502-502.
FULL TEXT  

Inflammation in the genesis and perpetuation of atrial fibrillation
Engelmann and Svendsen
Eur Heart J 2005;26:2083-2092.
ABSTRACT | FULL TEXT  

Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada
Austin and Mamdani
Circulation 2005;112:1296-1300.
ABSTRACT | FULL TEXT  

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication
Kessler et al.
Arch Gen Psychiatry 2005;62:593-602.
ABSTRACT | FULL TEXT  

Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen et al.
NEJM 2005;352:29-38.
ABSTRACT | FULL TEXT  

Management of dyslipidaemia
Thompson
Heart 2004;90:949-955.
FULL TEXT  

Intensive vs. Moderate Statin Therapy: Effect on Atherosclerosis Progression
Journal Watch Cardiology 2004;2004:2-2.
FULL TEXT